Thompson, M., Mato, A., Zelenetz, A., Park, J., Geyer, M., Derkach, A., Nemirovsky, D., Stephens, D., Coombs, C., Islam, P., Jensen, C., Falchi, L., Palomba, L., Kumar, A., Salles, G., Stein, E., Lue, J., Nogan, L., Kikani, B., Sutterby, R., Nguyen, T. Q., Allen, A., Sudhir, S., Panton, G., Duffy, V., Tyznar, D., Brutus, J., Nyima, T., Shah, A., Soni, D., Silvestrone, M., Shah, M., Harris, M., Karnam, M., Hutzler, C., David, K., Goldberg, A., Fleming, S., Diaz, G., Hamidi, H., Fakhri, B., Roeker, L. (2025). Updated results from a Phase II study of minimal residual disease-guided venetoclax + obinutuzumab for the initial treatment of fit patients with chronic lymphocytic leukemia. Blood. https://doi.org/10.1182/blood-2025-3902